Revlimid (Lenalidomide) (15 Milligram, Capsules)


Indications and Reactions:

Role Indications Reactions
Primary
Plasma Cell Myeloma 92.8%
Product Used For Unknown Indication 1.7%
Amyloidosis 1.4%
Lymphoma 1.4%
Myelodysplastic Syndrome 0.6%
Non-hodgkin's Lymphoma 0.6%
B-cell Lymphoma 0.3%
Diffuse Large B-cell Lymphoma 0.3%
Mantle Cell Lymphoma 0.3%
Neoplasm 0.3%
Pelvic Neoplasm 0.3%
Prostate Cancer 0.3%
Pneumonia 11.0%
White Blood Cell Count Decreased 9.9%
Thrombosis 9.4%
Plasma Cell Myeloma 8.9%
Drug Dose Omission 8.4%
Rash 6.3%
Platelet Count Decreased 5.8%
Diarrhoea 5.2%
Nasopharyngitis 4.7%
Neuropathy Peripheral 4.7%
Pulmonary Embolism 3.7%
Renal Failure 3.7%
Fatigue 3.1%
Malaise 2.6%
Anaemia 2.1%
Full Blood Count Decreased 2.1%
Hypoaesthesia 2.1%
Local Swelling 2.1%
Muscle Spasms 2.1%
Pruritus 2.1%
Concomitant
Plasma Cell Myeloma 100.0%
Platelet Count Decreased 100.0%

Drug Data